Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


The aim of this study was to reveal most clinically effective and economically expedient anti-H 1-receptor antagonist cetirizine generation (original or generic), to carry out the analysis of pharmaceutical equivalence of cetirizine generation anti-H-receptor antagonists manufactured by different companies. Materials and methods. Study is executed in design of simple open comparative prospective randomized research in parallel groups. The preliminary analysis of volume and structure of H-antihistamine cetirizine generation products retails for the purpose of definition of the most widespread trademarks was carried out 117 patients with chronic idiopathic urticaria (CIU) treated with various trademarks cetirizine 10 mg/day within 4 weeks were included in the study. Clinical efficiency criteria: dynamics of urticaria symptoms, change of index severity, remission period, days free from CIU symptoms. The pharmaceutical analysis included comparative studying of rate of dissolution and quantitative identification of medicinal substance. The pharmacoeconomic analysis was done by an «expense-efficiency» method. Results. All investigated drugs of cetirizine in a dose of 10 mg dayly significantly (p<0,001) reduced CIU symptoms. In mild CIU clinical efficiency of original and generic drugs had no significant differences but in severe CIU showed obvious superiority of an original drug (p<0,01). The greatest quantity of the patients reached pharmacological remission, received Zirtec and Cetrine. Coincidence of dissolution profiles with criteria of similarity for Zirtec, Cetrine and Parlazine and rate of substance liberation for Zirtec and Cetrine explained rapidity of achievement of therapeutic effect of investigated preparations. The best results from the point of view of economic efficiency were shown with Cetrine therapy. Use of original Zirtec was more expensive, but also more effective. Discussion. Results of the study demonstrated clinical efficiency of cetirizine family products belonged to different manufacturers depending on their bioavailability which had the following rating of efficiency: Cetrine > Parlazine > Cetirizine-Hexal > Zodak.

Full Text

Restricted Access

About the authors

E E Nekrasova

Volgograd State medical university


A V Ponomareva

Volgograd State medical university


T G Fedoskova

Institute of immunology

Email: tatger@mail.ru
Moscow, Russia


  1. Российский национальный согласительный документ «Крапивница и ангиоотек: рекомендации для практических врачей». Под ред. И.С. Гущина, Н.И. Ильиной. М., «Фармарус Принт Медиа». 2007, 128 с.
  2. Jauregui I., Ferrer M., Montoro J. et al. Antihistamines in the treatment of chronic urticaria. J. Investig. Allergol. Clin. Immunol. 2007, v. 17, Suppl. 2, p. 41-52.
  3. Данилычева И.В., Ильина Н.И. Качество жизни у больных крапивницей и атопическим дерматитом. Consilium Medicum. 2001, № 4, с. 184-186.
  4. Zuberbier T., Bindslev-Jensen C., Canonica W. et al. EAACI/ GA.LEN/EDF guideline: management of urticaria. Allergy. 2006, v. 61, p. 321-331.
  5. Wedi B., Kapp A. Evidence-based therapy of chronic urticaria. J. Dtsch. Dermatol. Ges. 2007, v. 5, p. 146-157.
  6. Kozel M.M., Sabroe R. Chronic Urticaria: etiology, management and current and future treatment options. Drug. 2004, v. 64 (22), p. 2516-2536.
  7. Федоскова Т.Г. Применение цетиризина (цетрин) в лечении больных круглогодичным аллергическим ринитом. Рос. Аллергол. Журн. 2006, № 5, c. 37-41.
  8. Волосовец А.П., Кривопустов С.П., Павлик Е.В. Роль аллергического воспаления в повседневной врачебной практике. Оптимизация противоаллергической терапии. Медицинская литература (Киев). 2010, № 1, с. 70-75.
  9. Grant J.A., Danielson L., Rihox J.P., De Vos C. A double-blind, single dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: suppression of histamine-induced wheal and fl are response for 24 h in healthy male subjects. Allergy. 1999,v. 54, p. 700-707.
  10. Татаурщикова Н.С. Современные аспекты применения антигистаминных препаратов. Детская и подростковая реабилитация. 2011, № 2, с. 66-71.
  11. Татаурщикова Н.С. Современные аспекты применения антигистаминных препаратов в практике врача-терапевта. Фарматека. 2011, № 11, с. 46-50.
  12. Гущин И.С. Потенциал противоаллергической активности и клиническая эффективность Н1-антагонистов. Аллергология. 2003, № 1, с. 8-12.
  13. Петров В.И., Смоленов И.В., Лопатин А.С. и соавт. Оптимизация фармакотерапии сезонного аллергического ринита у детей с позиции «затраты/эффективность». Рос. ринол. 2002, № 4, с. 19-22.
  14. Некрасова Е.Е., Разваляева А.В., Вергейчик Е.Н. и соавт. Сравнительная оценка биофармацевтических характеристик цетиризина в лекарственной форме различных производителей. Астраханский мед. журн. 2010, № 4, с. 51-55.
  15. Безуглый П.А., Болотов В.В., Гриценко И.С. и соавт. От субстанции к лекарству. Под ред. В.П. Черных. Харьков. «НФАУ Золотые страницы». 2005, 1244 с.



Abstract - 15

PDF (Russian) - 0


Article Metrics

Metrics Loading ...


Copyright (c) 2013 Russian Allergological Journal

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies